Research progress on immune checkpoint inhibitors in older patients with advanced non-small cell lung cancer / 中华老年医学杂志
Chinese Journal of Geriatrics
;
(12): 360-365, 2022.
Artigo
em Chinês
| WPRIM
| ID: wpr-933086
ABSTRACT
Lung cancer is one of the most common malignant neoplastic diseases in the elderly.Immunotherapy represented by immune checkpoint inhibitors mobilizes the body's immune system to achieve antitumor effects.Immune checkpoint inhibitors and their combination with other drugs have played an increasingly important role in the treatment of patients with advanced non-small cell lung cancer.In this review, we summarize the therapeutic effects, adverse reactions and hyperprogressive disease of immune checkpoint inhibitors in the elderly with advanced non-small cell lung cancer, in order to provide insight on immunotherapy strategies for non-small cell lung cancer in the elderly.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Geriatrics
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS